Legal & General Group Plc increased its position in shares of ICU Medical, Incorporated (NASDAQ:ICUI) by 18.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,686 shares of the medical instruments supplier’s stock after acquiring an additional 2,706 shares during the period. Legal & General Group Plc owned about 0.09% of ICU Medical worth $5,193,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in the stock. Millennium Management LLC raised its holdings in shares of ICU Medical by 5.9% during the first quarter. Millennium Management LLC now owns 548,769 shares of the medical instruments supplier’s stock worth $138,509,000 after acquiring an additional 30,676 shares in the last quarter. JPMorgan Chase & Co. increased its position in ICU Medical by 6.8% during the first quarter. JPMorgan Chase & Co. now owns 472,988 shares of the medical instruments supplier’s stock worth $119,382,000 after buying an additional 29,977 shares during the last quarter. Northern Trust Corp increased its position in ICU Medical by 21.3% during the first quarter. Northern Trust Corp now owns 246,976 shares of the medical instruments supplier’s stock worth $62,337,000 after buying an additional 43,410 shares during the last quarter. Point72 Asset Management L.P. increased its position in ICU Medical by 65.0% during the first quarter. Point72 Asset Management L.P. now owns 200,256 shares of the medical instruments supplier’s stock worth $50,545,000 after buying an additional 78,856 shares during the last quarter. Finally, Redmile Group LLC increased its position in ICU Medical by 38.2% during the first quarter. Redmile Group LLC now owns 193,472 shares of the medical instruments supplier’s stock worth $48,832,000 after buying an additional 53,500 shares during the last quarter. Institutional investors and hedge funds own 74.29% of the company’s stock.
ICUI traded up $4.95 during midday trading on Friday, reaching $265.80. 167,031 shares of the company’s stock were exchanged, compared to its average volume of 157,986. The stock has a market cap of $5.79 billion, a price-to-earnings ratio of 48.15 and a beta of 0.41. ICU Medical, Incorporated has a one year low of $180.45 and a one year high of $321.70.
ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 9th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.82 by $0.84. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. The company had revenue of $360.46 million during the quarter, compared to analysts’ expectations of $337.60 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. ICU Medical’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, analysts expect that ICU Medical, Incorporated will post 7.6 earnings per share for the current fiscal year.
In related news, Director Pfizer Inc sold 700,000 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $284.35, for a total value of $199,045,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Thomas D. Mccall sold 11,133 shares of ICU Medical stock in a transaction on Friday, August 24th. The stock was sold at an average price of $302.56, for a total transaction of $3,368,400.48. Following the sale, the vice president now directly owns 3,018 shares of the company’s stock, valued at approximately $913,126.08. The disclosure for this sale can be found here. Insiders sold a total of 711,920 shares of company stock valued at $202,651,956 in the last 90 days. 12.50% of the stock is currently owned by corporate insiders.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday. ValuEngine raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 28th. Finally, TheStreet raised ICU Medical from a “c+” rating to a “b+” rating in a research report on Monday, August 20th. One analyst has rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. ICU Medical has a consensus rating of “Buy” and an average target price of $337.00.
About ICU Medical
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.